CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in CNS Pharmaceuticals, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 7
- −13 vs. Q4 2024
- Shares held
- 40.6K
- −2.43M (−98.4%) vs. Q4 2024
- Total value
- $55.2K
- −$242.1K (−81.4%) vs. Q4 2024
- New holders
- 3
- 0 more added
- Sold out
- 16
- 4 more reduced
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CNSP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $1.34M |
| Q1 2026 | 12 | $348.7K |
| Q4 2025 | 10 | $652.4K |
| Q3 2025 | 8 | $221.5K |
| Q2 2025 | 11 | $421.8K |
| Q1 2025 | 7 | $55.2K |
| Q4 2024 | 21 | $297.3K |
| Q3 2024 | 14 | $75.3K |
| Q2 2024 | 10 | $227.8K |
| Q1 2024 | 19 | $351.0K |
| Q4 2023 | 16 | $425.3K |
| Q3 2023 | 12 | $131.7K |
| Q2 2023 | 12 | $234.4K |
| Q1 2023 | 13 | $190.5K |
| Q4 2022 | 10 | $335.0K |
| Q3 2022 | 21 | $232.0K |
| Q2 2022 | 23 | $343.5K |
| Q1 2022 | 20 | $589.0K |
| Q4 2021 | 24 | $828.0K |
| Q3 2021 | 20 | $1.44M |
| Q2 2021 | 20 | $2.64M |
| Q1 2021 | 19 | $3.04M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding CNS Pharmaceuticals, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 23,978 | $32.6K | 0.00% | −40,440−62.8% | Reduced |
| Ground Swell Capital, LLC | 11,341 | $15.4K | 0.04% | +11,341 | New |
| Tower Research Capital LLC (TRC) | 5,111 | $6.95K | 0.00% | +5,111 | New |
| Barrett & Company, Inc. | 100 | $136 | 0.00% | +100 | New |
| MAI Capital Management | 40 | $55 | 0.00% | −1,960−98.0% | Reduced |
| SBI Securities Co., Ltd. | 15 | $20 | 0.00% | −90−85.7% | Reduced |
| Bank of America Corp | 9 | $12 | 0.00% | −431−98.0% | Reduced |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −419,737−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −387,064−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −321,874−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −294,919−100.0% | Sold out |
| Connective Capital Management, LLC | 0 | $0 | 0.00% | −280,055−100.0% | Sold out |
| Integrated Wealth Concepts LLC | 0 | $0 | 0.00% | −250,000−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −162,349−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −156,007−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −93,077−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −40,329−100.0% | Sold out |
| Synergy Investment Management, LLC | 0 | $0 | 0.00% | −9−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Plante Moran Financial Advisors, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Dogwood Wealth Management LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Global Retirement Partners, LLC | – | – | – | – | Not filed |